Clinical Roundup NCI study: COVID-19 was third leading cause of death in the U.S. in 2020 and 2021 July 08, 2022Vol.48 No.27
NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups June 24, 2022Vol.48 No.25By Paul Goldberg and Alice Tracey
Conversation with The Cancer Letter Julie Bauman: Washington, DC, needs one more NCI-designated cancer center—and it matters that a woman runs it June 17, 2022Vol.48 No.24By Paul Goldberg
NCI Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0 June 17, 2022Vol.48 No.24By Alice Tracey
Trials & Tribulations ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV June 17, 2022Vol.48 No.24By Joel M. Palefsky and Robert Yarchoan
Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care June 10, 2022Vol.48 No.23By Alice Tracey
Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure May 27, 2022Vol.48 No.21By Paul Goldberg
Capitol Hill Cancer groups ask for $4.1 billion increase for NIH, $850 million boost for NCI in FY23 May 27, 2022Vol.48 No.21By Alice Tracey
